In HBL melanoma cells, 300 nM elesclomol–copper increased ROS-probe oxidation at 12 h and cell death at 24 h. Mitochondrial-DNA-depleted HBL-rho0 cells were resistant under the same conditions, and copper alone did not reproduce the cell-death response. [2]
In copper-deficient H9c2 Ctr1-knockout cells, elesclomol–copper restored COX1 abundance at concentrations below those reducing ATP-based viability. At 48 h, the COX1-restoration EC50 was 0.5 nM and the viability IC50 was 26 nM. These are distinct cellular endpoints, not treatment doses or a clinical safety margin. [1]
ETC dependence of elesclomol–copper responses in melanoma cells
Cell-based study · Human HBL melanoma cells and mitochondrial-DNA-depleted HBL-rho0 cells [2]
At 300 nM elesclomol–Cu, parental HBL cells showed increased probe oxidation at 12 h and cell death at 24 h; HBL-rho0 cells were resistant under these conditions. Copper alone did not reproduce cell death. These results establish dependence on the tested cellular mitochondrial state, without identifying a single direct protein target or proving that all elesclomol-induced death is apoptotic.
Literature-Reported Treatment Conditions
- Treatment concentration
- 300 nM elesclomol–Cu; copper-only comparator at 300 nM
- Exposure duration
- 12 h for ROS probe; 24 h for cell-death analysis
- Method
- Flow cytometry: hydroxyethidium oxidation and propidium iodide staining; Figure 5 also displays DiOC6(3).
- Vehicle
- Untreated controls shown; solvent concentration for this experiment is not specified in the relevant subsection.
- Reported limits
- Do not borrow the 0.3% DMSO used for the separate Hs294T combination assay. Figure 5A is representative of three independent experiments; Figure 5B does not separately state replication.
Methods and source locations
Compound reported in the paper: Elesclomol; Compound label in the paper: Elesclomol–copper complex (elesclomol-Cu)
Applies to elesclomol supplied with copper as the tested complex; not a ligand-alone potency claim.
Results: Human cells lacking ETC activities are insensitive to elesclomol; Figure 5A–B; Methods: Reagents and Cytofluorometric analyses of rho0 Melanoma Cell Lines
Probe oxidation in parental versus rho0 melanoma cells: Hydroxyethidium flow cytometry after 300 nM elesclomol-Cu for 12 h; representative of three independent experiments — Figure 5A and corresponding Results/Methods
Cell death compared with untreated and copper-only controls: Propidium iodide flow cytometry after 24 h; Figure 5B also shows mitochondrial-potential dye — Figure 5B and corresponding Results/Methods
COX1 restoration and viability concentration responses in copper-deficient cells
Cell-based study · Rat H9c2 wild-type and Ctr1-knockout cells [1]
ES-Cu restored COX1 abundance in copper-deficient Ctr1-knockout cells at lower concentrations than those that reduced ATP-based viability. At 48 h, the COX1-restoration EC50 was 0.5 nM, whereas viability IC50 values were 25 nM in WT and 26 nM in knockout cells. This assay-specific separation is not a clinical therapeutic index.
Literature-Reported Treatment Conditions
- Treatment concentration
- Viability: 0.1, 0.5, 1, 5, 10, 50 and 100 nM; COX1: 0.1, 0.5, 1 and 5 nM ES-Cu
- Exposure duration
- 24, 48 and 72 h
- Method
- CellTiter-Glo ATP-based viability; SDS-PAGE/immunoblotting for COX1 normalized to ATP5A and vehicle control.
- Vehicle
- DMSO (≤0.1%)
Methods and source locations
Compound reported in the paper: Elesclomol; Compound label in the paper: Elesclomol–copper complex (ES-Cu)
Complex-specific cellular assay endpoints; COX1 abundance is a protein-rescue readout, not direct enzyme activity.
Results 3.1; Figure 2A–K; Methods 2.1, 2.2, 2.5, 2.6, 2.10
ATP-based cell viability after ES-Cu treatment: CellTiter-Glo; fitted concentration-response values; n = 3 biological replicates with three technical replicates; data expressed as mean ± SD — Figure 2A–D (values printed in D); Methods 2.5 and 2.10
Restoration of COX1 abundance in Ctr1-knockout cells: COX1 immunoblot signal normalized to ATP5A and vehicle; n = 3 biological replicates, mean ± SD — Figure 2E–K (values printed in K); Results 3.1; Methods 2.6 and 2.10
Concentration dependence of copper-toxicity protein markers
Cell-based study · Rat H9c2 wild-type and Ctr1-knockout cells [1]
After 18 h of ES-Cu exposure, lipoylated DLAT/DLST and selected Fe-S protein signals decreased with concentration, while higher-order DLAT complexes increased at higher concentrations. ACO2 was an exception: its abundance did not show the corresponding reduction and an IC50 was not determined. These are cuproptosis-associated molecular readouts; the experiment does not establish an exclusive death pathway.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0 (DMSO), 1, 5, 10, 25, 50 and 100 nM ES-Cu
- Exposure duration
- 18 h
- Method
- Immunoblot concentration-response analysis of Fe-S proteins and lipoylated proteins; nonreducing electrophoresis/immunoblotting for DLAT oligomers.
- Vehicle
- DMSO; cell-culture stock described in Methods 2.1; exact final solvent percentage for Figure 4 is not separately specified.
- Reported limits
- Uncropped SI blots and fitted-data supplement were not retrieved. No unreported precision or confidence interval is assigned to printed point estimates.
Methods and source locations
Compound reported in the paper: Elesclomol; Compound label in the paper: Elesclomol–copper complex (ES-Cu)
Complex-specific molecular-marker responses in rat cells, not ligand-alone biochemical inhibition constants.
Results 3.3; Figure 4A–I; Methods 2.1, 2.2, 2.6, 2.10
Reduction in immunoblot abundance of Fe-S proteins: 18 h; immunoblot band-intensity fits; ATP5A and beta-actin controls; n = 3 biological replicates; N.D. means not determined — Figure 4A–C (printed table C); Results 3.3; Methods 2.10
Reduction in lipoylated DLAT and DLST signals: 18 h; anti-lipoic-acid immunoblot concentration-response fits; n = 3 biological replicates — Figure 4D–F (printed table F); Results 3.3; Methods 2.10
Increase in higher-order DLAT immunoblot bands: 18 h; nonreducing immunoblots; combined bands above 75 kDa normalized to vehicle; n = 3 biological replicates — Figure 4G–I (printed table I); Results 3.3; Methods 2.10